亚太地区家庭输液治疗市场预测至 2028 年 - COVID-19 影响和按产品(输液泵、静脉注射器、静脉插管和无针连接器)、应用(抗感染、内分泌、肠内营养、水化治疗、化疗、特殊药物等)和给药途径(肌内、皮下和硬膜外)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028


No. of Pages: 164    |    Report Code: BMIRE00028356    |    Category: Life Sciences

Asia Pacific Home Infusion Therapy Market

亚太家庭输液治疗市场预计将从 2022 年的 33.4035 亿美元增长到 2028 年的 57.2565 亿美元。预计 2022 年至 2028 年复合年增长率为 9.4% 2028年。

发展中经济体的医疗保健潜力不断增强,医疗保健相关的普及率不断上升

感染正在推动亚太地区家庭输液治疗市场

发展中国家报告称,由于人们生活习惯的显着变化,慢性病患病率很高。的生活方式。领先的制药公司一直致力于通过扩大分销网络和增强制造能力来扩大其在新兴市场的影响力。

在发展中国家,接受家庭输液的患者数量过去治疗受到限制。尽管医院已迅速采用集成了电子健康记录 (EHR) 集成和用药安全软件等功能的智能输液泵,但大多数家庭输液服务提供商仍然使用传统输液泵。然而,发展中国家专注于改善其医疗基础设施和服务,这鼓励医疗保健部门升级这些产品和服务。此外,研发方面的大量投资对新兴国家产品和服务的技术升级发挥着关键作用。随着此类升级医疗服务的可用性不断增加,未来这些国家的使用量可能会增加。

由于 COVID-19 大流行,医院承受着巨大的压力为了照顾大量患者,导致急诊室 (ER) 人满为患,医生和医务人员不堪重负;因此,发展中国家的医疗保健部门发生了向家庭护理环境的重大转变。此外,由于担心感染 COVID-19,许多患者退出了医院内的治疗,因此家庭护理成为一个不错的选择。此外,患者在医院或其他医疗机构接受服务时容易发生医院获得性感染或医疗保健相关感染(HAI)。医院感染的发病率和死亡率很高,每年给医疗保健系统造成数十亿美元的损失。随着感染率不断上升,人们越来越关注降低医院感染的发病率,因为治疗这些感染所需的巨额费用会给医疗保健系统带来额外的经济负担。因此,由于COVID-19大流行,家庭输液被认为是降低HAI风险的有效治疗选择,这为家庭输液治疗市场提供了重要机遇。

亚太地区家庭输液治疗市场概览

亚太地区家庭输液治疗市场分为中国、日本、印度、韩国、澳大利亚和亚太地区其他地区。中国在 2021 年占据最大的市场份额,印度预计该市场的复合年增长率将大幅提高。这些国家的市场增长归因于慢性病患病率的增加、老年人口的增加、家庭输液治疗提供者的增加以及政府举措的增加。中国政府提出了“健康中国2030”,以促进国内医疗保健服务,同时为全球带来巨大利益。该国人口更容易患传染病、慢性病和急性病。中国面临着肺癌、结直肠癌、食道癌、心脏病和糖尿病的高负担。此外,本土主要企业的不断壮大正在推动中国家庭输液治疗市场的增长。制造商正致力于扩大其全球战略影响力和具有独特技术能力的专业知识,从而扩大中国家庭输液治疗市场。因此,糖尿病和慢性病患病率的上升、老年人口的增加以及区域参与者数量的激增预计将推动预测期内中国家庭输液治疗市场的增长。

亚太地区家庭输液治疗市场收入及 2028 年预测(百万美元)

亚太地区家庭输液治疗市场细分

亚太地区家庭输液治疗市场分为产品、应用、给药途径和国家。

根据产品,家庭输液治疗市场分为输液泵、静脉注射装置、IV 插管和无针连接器。家庭输液治疗市场细分为胰岛素泵、弹性泵、注射泵等。 2022年,输液泵细分市场占据最大市场份额。

根据应用,家庭输液治疗市场细分为肠内营养、抗感染、内分泌、水化疗法、化疗、特种药物等。 2022年,抗感染药物占据最大市场份额。

根据给药途径,家庭输液治疗市场分为肌内注射、皮下注射和硬膜外注射。 2022 年,肌肉注射细分市场占据最大市场份额。

按国家/地区划分,亚太地区家庭输液治疗市场分为澳大利亚、中国、印度、日本、韩国以及亚太地区其他地区。 2022 年,中国将主导市场。

B.布劳恩·梅尔松根股份公司;百特国际公司;尼普罗公司;贝克顿·迪金森公司;费森尤斯·卡比股份公司; ICU 医疗公司; JMS有限公司; Terumo Corp 是亚太家庭输液治疗市场的领先公司。



Asia Pacific Home Infusion Therapy Strategic Insights

Strategic insights for Asia Pacific Home Infusion Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-home-infusion-therapy-market-strategic-framework.webp
Get more information on this report

Asia Pacific Home Infusion Therapy Report Scope

Report Attribute Details
Market size in 2022 US$ 3,340.35 Million
Market Size by 2028 US$ 5,725.65 Million
Global CAGR (2022 - 2028) 9.4%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By 产品
  • 输液泵
  • 静脉注射套件
  • 静脉插管
  • 无针连接器
By 应用
  • 抗感染
  • 内分泌
  • 肠内营养
  • 水合疗法
  • 化疗
  • 专科药物
By 给药途径
  • 肌肉注射
  • 皮下注射
  • 硬膜外注射
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • B. Braun Melsungen AG
  • Baxter International Inc
  • Nipro Corp
  • Becton Dickinson and Co
  • Fresenius Kabi AG
  • ICU Medical Inc
  • JMS Co Ltd
  • Terumo Corp
  • Get more information on this report

    Asia Pacific Home Infusion Therapy Regional Insights

    The regional scope of Asia Pacific Home Infusion Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-home-infusion-therapy-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Home Infusion Therapy Market

    1. B. Braun Melsungen AG
    2. Baxter International Inc
    3. Nipro Corp
    4. Becton Dickinson and Co
    5. Fresenius Kabi AG
    6. ICU Medical Inc
    7. JMS Co Ltd
    8. Terumo Corp
    Frequently Asked Questions
    How big is the Asia Pacific Home Infusion Therapy Market?

    The Asia Pacific Home Infusion Therapy Market is valued at US$ 3,340.35 Million in 2022, it is projected to reach US$ 5,725.65 Million by 2028.

    What is the CAGR for Asia Pacific Home Infusion Therapy Market by (2022 - 2028)?

    As per our report Asia Pacific Home Infusion Therapy Market, the market size is valued at US$ 3,340.35 Million in 2022, projecting it to reach US$ 5,725.65 Million by 2028. This translates to a CAGR of approximately 9.4% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Home Infusion Therapy Market report typically cover these key segments-

  • 产品 (输液泵, 静脉注射套件, 静脉插管, 无针连接器)
  • 应用 (抗感染, 内分泌, 肠内营养, 水合疗法, 化疗, 专科药物)
  • 给药途径 (肌肉注射, 皮下注射, 硬膜外注射)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Home Infusion Therapy Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Home Infusion Therapy Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Asia Pacific Home Infusion Therapy Market?

    The Asia Pacific Home Infusion Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • B. Braun Melsungen AG
  • Baxter International Inc
  • Nipro Corp
  • Becton Dickinson and Co
  • Fresenius Kabi AG
  • ICU Medical Inc
  • JMS Co Ltd
  • Terumo Corp
  • Who should buy this report?

    The Asia Pacific Home Infusion Therapy Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Home Infusion Therapy Market value chain can benefit from the information contained in a comprehensive market report.